Cargando…
The case for FAT10 as a novel target in fatty liver diseases
Human leukocyte antigen F locus adjacent transcript 10 (FAT10) is a ubiquitin-like protein that targets proteins for degradation. TNFα and IFNγ upregulate FAT10, which increases susceptibility to inflammation-driven diseases like nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatiti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665838/ https://www.ncbi.nlm.nih.gov/pubmed/36386217 http://dx.doi.org/10.3389/fphar.2022.972320 |
_version_ | 1784831373819772928 |
---|---|
author | Wimalarathne, Madushika M. Wilkerson-Vidal, Quiana C. Hunt, Emily C. Love-Rutledge, Sharifa T. |
author_facet | Wimalarathne, Madushika M. Wilkerson-Vidal, Quiana C. Hunt, Emily C. Love-Rutledge, Sharifa T. |
author_sort | Wimalarathne, Madushika M. |
collection | PubMed |
description | Human leukocyte antigen F locus adjacent transcript 10 (FAT10) is a ubiquitin-like protein that targets proteins for degradation. TNFα and IFNγ upregulate FAT10, which increases susceptibility to inflammation-driven diseases like nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC). It is well established that inflammation contributes to fatty liver disease, but how inflammation contributes to upregulation and what genes are involved is still poorly understood. New evidence shows that FAT10 plays a role in mitophagy, autophagy, insulin signaling, insulin resistance, and inflammation which may be directly associated with fatty liver disease development. This review will summarize the current literature regarding FAT10 role in developing liver diseases and potential therapeutic targets for nonalcoholic/alcoholic fatty liver disease and hepatocellular carcinoma. |
format | Online Article Text |
id | pubmed-9665838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96658382022-11-15 The case for FAT10 as a novel target in fatty liver diseases Wimalarathne, Madushika M. Wilkerson-Vidal, Quiana C. Hunt, Emily C. Love-Rutledge, Sharifa T. Front Pharmacol Pharmacology Human leukocyte antigen F locus adjacent transcript 10 (FAT10) is a ubiquitin-like protein that targets proteins for degradation. TNFα and IFNγ upregulate FAT10, which increases susceptibility to inflammation-driven diseases like nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC). It is well established that inflammation contributes to fatty liver disease, but how inflammation contributes to upregulation and what genes are involved is still poorly understood. New evidence shows that FAT10 plays a role in mitophagy, autophagy, insulin signaling, insulin resistance, and inflammation which may be directly associated with fatty liver disease development. This review will summarize the current literature regarding FAT10 role in developing liver diseases and potential therapeutic targets for nonalcoholic/alcoholic fatty liver disease and hepatocellular carcinoma. Frontiers Media S.A. 2022-11-01 /pmc/articles/PMC9665838/ /pubmed/36386217 http://dx.doi.org/10.3389/fphar.2022.972320 Text en Copyright © 2022 Wimalarathne, Wilkerson-Vidal, Hunt and Love-Rutledge. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wimalarathne, Madushika M. Wilkerson-Vidal, Quiana C. Hunt, Emily C. Love-Rutledge, Sharifa T. The case for FAT10 as a novel target in fatty liver diseases |
title | The case for FAT10 as a novel target in fatty liver diseases |
title_full | The case for FAT10 as a novel target in fatty liver diseases |
title_fullStr | The case for FAT10 as a novel target in fatty liver diseases |
title_full_unstemmed | The case for FAT10 as a novel target in fatty liver diseases |
title_short | The case for FAT10 as a novel target in fatty liver diseases |
title_sort | case for fat10 as a novel target in fatty liver diseases |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665838/ https://www.ncbi.nlm.nih.gov/pubmed/36386217 http://dx.doi.org/10.3389/fphar.2022.972320 |
work_keys_str_mv | AT wimalarathnemadushikam thecaseforfat10asanoveltargetinfattyliverdiseases AT wilkersonvidalquianac thecaseforfat10asanoveltargetinfattyliverdiseases AT huntemilyc thecaseforfat10asanoveltargetinfattyliverdiseases AT loverutledgesharifat thecaseforfat10asanoveltargetinfattyliverdiseases AT wimalarathnemadushikam caseforfat10asanoveltargetinfattyliverdiseases AT wilkersonvidalquianac caseforfat10asanoveltargetinfattyliverdiseases AT huntemilyc caseforfat10asanoveltargetinfattyliverdiseases AT loverutledgesharifat caseforfat10asanoveltargetinfattyliverdiseases |